Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 21.3 -0.13 (-0.61%) Market Cap: 1.93 Bil Enterprise Value: 1.64 Bil PE Ratio: 0 PB Ratio: 4.38 GF Score: 39/100

Rocket Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript

Sep 11, 2019 / 03:40PM GMT
Release Date Price: $13.57 (+3.19%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good morning, and thank you very much for coming to the Morgan Stanley Healthcare Conference. Before I get going, let me read the requisite disclosures. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.

I'm Dave Lebowitz, one of the biotechnology analysts here, and I'm happy to have with me from Rocket Pharmaceuticals, CEO, Dr. Gaurav Shah. Rocket is a development-stage gene therapy company and developing treatments for rare diseases. So I guess if you could start by giving a background of the company and your overall approach to developing gene therapies and the mission.

Gaurav Shah
Rocket Pharmaceuticals, Inc. - CEO, President & Director

Sure. Thanks for having me here. It's been a year. We're just talking about this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot